1. Landen CN Jr, Birrer MJ, Sood AK. Early genetic events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6): 995-1005, 2008.
2. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice M, Sood AK. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10(11): 1259-67, 2008.
3. Kim T*, Landen CN*, Lin YG, Mangala L, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings N, Coleman RL, Tice D, Sood AK. Combined targeting of VEGF and alphavbeta3 in ovarian cancer. Can Biol Ther 8(23): 2263-73, 2009. †
4. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Jr., Coleman RL, Berestein G, and Sood AK. Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Molecular Cancer Therapeutics 9(12): 3186-99, 2010. †
5. Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, Gershenson DM, Landen Jr CN. Preoperative Factors Predicting Survival After Secondary Cytoreduction for Recurrent Ovarian Cancer. Int J Gyn Cancer, 21(5): 831-6, 2011.
6. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer. Clin Can Res, 17(17): 5674-85, 2011.
7. Steg AS, Bevis KS, Katre AA, Ziebarth A, Alvarez RD, Zhang K, Conner M, Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Can Res, 18(3):869-81, 2012.
8. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Wei H, Gershenson H, Matsuo K, Shahzad MMK, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic Thrombocytosis in Ovarian Cancer. NEJM, 366(7): 610-8, 2012.
9. Steg AS, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MS, Alvarez RD, Landen CN. Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer. Mol Cancer Ther, 11(7): 1587-97, 2012. †
10. Ziebarth AJ, Nowsheen S, Steg AS, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner MG, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Can Res, in press.